Home / Companies / Kymera Therapeutics, Inc. / 25 Jun 2025
Kymera Therapeutics, Inc.: meeting of 25 Jun 2025
Votes reported on Form N-PX, item by item
292 Form N-PX filers reported votes at the Kymera Therapeutics, Inc. meeting of 25 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 57.8% of reported votes for; 62 filers withheld from or voted against at least one nominee.
412 vote records from 119 filers. 37 of the 118 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
417 vote records from 292 filers. 69 of the 278 filers that marked the item either way voted against management. 14 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
206 vote records from 119 filers. 3 of the 118 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | Split or no vote | For | For |
| Fidelity | For | For | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | For | For | For |
| Franklin Templeton | Abstain or withhold * | For | For |
| Invesco | For | For | For |
| Equitable | Abstain or withhold * | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | For | Against * | For |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | For | Against * | For |
| Jackson National funds | Abstain or withhold * | For | For |
| Northern Trust and FlexShares | Abstain or withhold * | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | Abstain or withhold | For | For |
| Voya | Abstain or withhold * | For | For |
| First Trust | Abstain or withhold * | For | For |
| Russell Investments | Split or no vote | Against * | For |
| Nationwide | Split or no vote | Against * | For |
| Victory Capital | Abstain or withhold * | For | For |
| Brighthouse Funds | For | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| Columbia Threadneedle | Split or no vote | For | For |
| BNY Mellon | Abstain or withhold * | For | For |
| Principal | For | For | For |
| Capital Group and American Funds | For | Against * | For |
| Pacific Life funds | Abstain or withhold * | Against * | For |
| Global X | For | Against * | For |
| MFS | Abstain or withhold * | Against * | For |
| Transamerica | For | For | For |
| AllianceBernstein | No report | For | No report |
| Hartford Funds | For | For | For |
| DWS | Abstain or withhold * | For | For |
| MassMutual | For | For | For |
| Harbor Funds | For | For | For |
| Janus Henderson | No report | For | No report |
| Neuberger Berman | No report | Against * | No report |
| Natixis and Loomis Sayles | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Kymera Therapeutics, Inc. meeting?
292 Form N-PX filers reported votes at the meeting of 25 Jun 2025. On say-on-pay, 69 of 278 voted against management (24.8%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Kymera Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Kymera Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Kymera Therapeutics, Inc. with a meeting date within three days of 25 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.